Xbrane Biopharma (Sweden) Performance
| XBRANE Stock | SEK 0.18 0.01 5.26% |
On a scale of 0 to 100, Xbrane Biopharma holds a performance score of 4. The firm maintains a market beta of -0.61, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Xbrane Biopharma are expected to decrease at a much lower rate. During the bear market, Xbrane Biopharma is likely to outperform the market. Please check Xbrane Biopharma's downside variance, as well as the relationship between the daily balance of power and period momentum indicator , to make a quick decision on whether Xbrane Biopharma's historical returns will revert.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Xbrane Biopharma AB are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. Despite somewhat uncertain basic indicators, Xbrane Biopharma sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 243.1 M | |
| Total Cashflows From Investing Activities | -77.3 M |
Xbrane |
Xbrane Biopharma Relative Risk vs. Return Landscape
If you would invest 16.00 in Xbrane Biopharma AB on August 29, 2024 and sell it today you would earn a total of 2.00 from holding Xbrane Biopharma AB or generate 12.5% return on investment over 90 days. Xbrane Biopharma AB is generating 0.3856% of daily returns and assumes 6.5551% volatility on return distribution over the 90 days horizon. Simply put, 58% of stocks are less volatile than Xbrane, and 93% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Xbrane Biopharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Xbrane Biopharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Xbrane Biopharma AB, and traders can use it to determine the average amount a Xbrane Biopharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0588
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | XBRANE | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.56 actual daily | 58 58% of assets are less volatile |
Expected Return
| 0.39 actual daily | 7 93% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average Xbrane Biopharma is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Xbrane Biopharma by adding it to a well-diversified portfolio.
Xbrane Biopharma Fundamentals Growth
Xbrane Stock prices reflect investors' perceptions of the future prospects and financial health of Xbrane Biopharma, and Xbrane Biopharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Xbrane Stock performance.
| Return On Equity | -0.37 | |||
| Return On Asset | -0.13 | |||
| Operating Margin | (4.61) % | |||
| Current Valuation | 2.32 B | |||
| Shares Outstanding | 27.51 M | |||
| Price To Earning | (10.92) X | |||
| Price To Book | 7.49 X | |||
| Price To Sales | 75.09 X | |||
| Revenue | 11.53 M | |||
| EBITDA | (172.74 M) | |||
| Cash And Equivalents | 44.32 M | |||
| Cash Per Share | 5.34 X | |||
| Total Debt | 36.48 M | |||
| Debt To Equity | 48.90 % | |||
| Book Value Per Share | 12.99 X | |||
| Cash Flow From Operations | (219.61 M) | |||
| Earnings Per Share | (7.13) X | |||
| Total Asset | 688.43 M | |||
| Retained Earnings | (29 M) | |||
| Current Asset | 77 M | |||
| Current Liabilities | 13 M | |||
About Xbrane Biopharma Performance
By analyzing Xbrane Biopharma's fundamental ratios, stakeholders can gain valuable insights into Xbrane Biopharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Xbrane Biopharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Xbrane Biopharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Xbrane Biopharma AB , a biopharmaceutical company, develops and manufactures biosimilars and generic long acting injectables. Xbrane Biopharma AB was founded in 2008 and is headquartered in Solna, Sweden. Xbrane Biopharma operates under Pharmaceuticals And Biosciences classification in Sweden and is traded on Stockholm Stock Exchange. It employs 35 people.Things to note about Xbrane Biopharma performance evaluation
Checking the ongoing alerts about Xbrane Biopharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Xbrane Biopharma help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Xbrane Biopharma had very high historical volatility over the last 90 days | |
| Xbrane Biopharma has some characteristics of a very speculative penny stock | |
| The company reported the revenue of 11.53 M. Net Loss for the year was (188.38 M) with loss before overhead, payroll, taxes, and interest of (18.27 M). | |
| Xbrane Biopharma AB has accumulated about 44.32 M in cash with (219.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.34, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 35.0% of the company outstanding shares are owned by insiders |
- Analyzing Xbrane Biopharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Xbrane Biopharma's stock is overvalued or undervalued compared to its peers.
- Examining Xbrane Biopharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Xbrane Biopharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Xbrane Biopharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Xbrane Biopharma's stock. These opinions can provide insight into Xbrane Biopharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Xbrane Stock analysis
When running Xbrane Biopharma's price analysis, check to measure Xbrane Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Xbrane Biopharma is operating at the current time. Most of Xbrane Biopharma's value examination focuses on studying past and present price action to predict the probability of Xbrane Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Xbrane Biopharma's price. Additionally, you may evaluate how the addition of Xbrane Biopharma to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |